Breaking News Instant updates and real-time market news.

MNK

Mallinckrodt

$23.89

0.57 (2.44%)

, KSS

Kohl's

$55.16

1.5 (2.80%)

09:55
12/26/17
12/26
09:55
12/26/17
09:55

Early notable gainers among liquid option names on December 26th

Notable gainers among liquid option names this morning include Mallinckrodt (MNK) $24.53 +1.22, Kohl's (KSS) $55.79 +2.12, Macy's (M) $26.59 +0.90, Foot Locker (FL) $48.58 +1.34, and Signet Jewelers (SIG) $58.04 +1.43.

MNK

Mallinckrodt

$23.89

0.57 (2.44%)

KSS

Kohl's

$55.16

1.5 (2.80%)

M

Macy's

$26.52

0.85 (3.31%)

FL

Foot Locker

$48.32

1.0632 (2.25%)

SIG

Signet Jewelers

$58.24

1.64 (2.90%)

  • 08

    Jan

  • 10

    Jan

  • 23

    Jan

  • 24

    Jan

  • 27

    Feb

  • 18

    Mar

MNK Mallinckrodt
$23.89

0.57 (2.44%)

12/12/17
LEHM
12/12/17
NO CHANGE
Target $23
LEHM
Equal Weight
Mallinckrodt management keeps conviction in Acthar, says Barclays
Barclays analyst Douglas Tsao says Mallinckrodt management in meetings last week reiterated their conviction in the Acthar franchise's durability. The analyst continues to believe the franchise should prove "reasonably durable," but after Q3's miss, he does not expect a "v-shaped" recovery next year. Further, Acthar,'s pressure could worsen if additional payers implement policies that affected Q3, Tsao tells investors in a research note titled "It always comes back to Acthar." The analyst keeps an Equal Weight rating on Mallinckrodt with a $23 price target.
11/22/17
11/22/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Salesforce (CRM) downgraded to Neutral from Buy at Roth Capital with analyst Richard Baldry citing the 59% year-to-date rally in the shares. 2. Bloomin' Brands (BLMN) downgraded to Neutral from Buy at BofA/Merrill with analyst Gregory Francfort citing news of Jana Partners' 8.7% stake and subsequent share price spike. 3. Halozyme (HALO) assumed with an Equal Weight from Overweight at Barclays with analyst Gena Wang saying she believes the potential of Halozyme's Enhanze technology is largely reflected in the stock following the recent rally. 4. Mallinckrodt (MNK) downgraded to Perform from Outperform at Oppenheimer with analyst Derek Archila saying he's been "flat out wrong" on the shares. 5. Cytokinetics (CYTK) was downgraded to Neutral from Overweight at Cantor Fitzgerald and to Buy from Strong Buy at Needham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/22/17
WELS
12/22/17
NO CHANGE
WELS
Market Perform
Wells says tax act net effect seems positive for Mallinckrodt non-GAAP EPS
After Mallinckrodt released a regulatory filing this morning stating the company's anticipated puts and takes related to the passage of the U.S. Tax Cut and Jobs Act, Wells Fargo analyst David Maris said he believes the net effect of the TCJA seems positive for the company's non-GAAP EPS. Maris keeps a Market Perform rating on Mallinckrodt shares.
11/22/17
OPCO
11/22/17
DOWNGRADE
OPCO
Perform
Mallinckrodt downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Derek Archila downgraded Mallinckrodt to Perform saying he's been "flat out wrong" on the shares. The thesis of branded growth and material margin expansion has not and is unlikely to play out within the next 12-18 months, Archila tells investors in a research note. He sees "little-to-no visibility" on Acthar growth outside of management's remarks on the payer pushback/patient abandonment issues. Further, Archila is not certain whether the company can remedy the Acthar growth issue in a timely manner. He pulled his price target for Mallinckrodt shares.
KSS Kohl's
$55.16

1.5 (2.80%)

11/29/17
DADA
11/29/17
NO CHANGE
Target $1500
DADA
Buy
Amazon.com price target raised to $1,500 from $1,300 at DA Davidson
DA Davidson analyst Tom Forte raised his price target on Amazon (AMZN) shares to $1,500 from $1,300 after increasing his long-term sales forecast to a 9.8% CAGR from 8.6% based on his rising confidence in the company's ability to leverage physical stores to maximize its long-term revenue growth. Amazon's increased physical footprint, including its Whole Foods buy, book stores, and Kohl's (KSS) partnership, is "THE story of its 2017 holiday sales and an indication of things to come," Forte tells investors. The analyst, who thinks Amazon could another 1,000 plus physical locations and acquire an apparel retailer, such as lululemon (LULU), keeps a Buy rating on the e-commerce giant's shares.
12/08/17
NRCS
12/08/17
INITIATION
NRCS
Neutral
Kohl's initiated with a Neutral at Northcoast
12/22/17
MSCO
12/22/17
NO CHANGE
MSCO
TJX stands to benefit from Bon-Ton closures, says Morgan Stanley
After analyzing which department stores and off-price retailers have the greatest overlap with troubled retailer Bon-Ton Stores (BONT), Morgan Stanley analyst Kimberly Greenberger found that over 40% of Bon-Ton's have a TJX (TJX) concept within a one mile radius and she sees it as the retailer that could benefit the most from a Bon-Ton liquidity event. Though Sears (SHLD) has the greatest overlap overall, there is no evidence to suggest it, nor Kohl's (KSS) and J.C. Penney (JCP), have been able to capitalize on Bon-Ton's struggles so far, added Greenberger.
12/07/17
CLVD
12/07/17
NO CHANGE
CLVD
Kohl's Q4 comps trending above consensus, says Cleveland Research
Cleveland Research's checks indicate Kohl's Q4 comps are trending above consensus and the channel is generally positive on the holiday season outlook.
M Macy's
$26.52

0.85 (3.31%)

12/18/17
OTRG
12/18/17
UPGRADE
OTRG
Mixed
Macy's upgraded to Mixed from Negative at OTR Global
OTR Global upgraded Macy's to Mixed following checks that indicate sell-through is meeting or exceeding plan driven by strong ecommerce trends.
12/07/17
CLVD
12/07/17
NO CHANGE
CLVD
Macy's Q4 sales appear to be improving, says Cleveland Research
10/30/17
10/30/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. General Motors (GM) downgraded to Sell from Neutral at Goldman Sachs with analyst David Tamberrino saying his price target of $32 offers 28% potential downside. The analyst continues to believe the North America auto cycle has peaked and he remains cautious on the sector. 2. Merck (MRK) downgraded to Hold from Buy at SunTrust and to Equal Weight from Overweight at Morgan Stanley, as well as Barclays. 3. J.C. Penney (JCP) downgraded to Sell from Neutral at Citi, to Neutral from Buy at Northcoast, and to Neutral from Positive at Susquehanna. 4. Macy's (M) downgraded to Sell from Neutral at Citi with analyst Paul Lejuez saying the retailer's sales and margins have been pressured for several years, and J.C. Penney's weak third quarter preannouncement on Friday serves as reminder of just how challenging the department store space is. 5. Under Armour (UAA, UA) downgraded to Underperform from Neutral at BofA/Merrill with analyst Robert Ohmes saying he expects management to lower fourth quarter guidance on its Q3 conference call due to the highly promotional environment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/09/17
JEFF
11/09/17
NO CHANGE
Target $20
JEFF
Hold
Jefferies sees some 'green shoots,' trims Macy's target to $20
Jefferies analyst Randal Konik says closely managed inventory lead to gross margin upside in Macy's Q3, which offset comp weakness. The analyst likes Macy's steps to drive traffic with initiatives across marketing, merchandising, and omni capabilities. He remains "guarded," however, around the secular headwinds in the mall-based department store space. In a post-earnings research note titled "Some Green Shoots Here, But We Remain Guarded L-Term," Konik lowered his price target for Macy's shares to $20 from $21 and keeps a Hold rating on the name.
FL Foot Locker
$48.32

1.0632 (2.25%)

12/15/17
12/15/17
UPGRADE
Target $64

Buy
Foot Locker upgraded to Buy on end of inventory clearance at Canaccord
As previously reported, Canaccord analyst Camilo Lyon upgraded Foot Locker (FL) to Buy from Hold, stating that he believes the company is approaching the end of the inventory clearance cycle it has been in for the past three quarters. His recent travels with management made it clear that the company's relationship with Nike (NKE) is "strong and symbiotic" and that recent comp declines are due to cyclical factors, not structural ones, he added. Lyon raised his price target on Foot Locker shares to $64 from $42.
12/15/17
12/15/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Foot Locker (FL) upgraded to Buy from Hold by Canaccord analyst Camilo Lyon, who believes the company is approaching the end of the inventory clearance cycle it has been in for the past three quarters and that the company's relationship with Nike (NKE) is "strong and symbiotic." 2. Stifel analyst Jim Duffy upgraded Under Armour (UAA) to Buy from Hold, saying he expects the company's business to be in a much better position entering 2019 and for the stock to begin to anticipate improvements before it shows in reported results. 3. Argus analyst John Staszak upgraded Skechers (SKX) to Buy from Hold with a price target of $44, citing signs that a recovery in the company's domestic wholesale business has commenced. 4. Goldman analyst Robert Jones upgraded AmerisourceBergen (ABC) to Buy from Neutral, telling investors he believes an EBIT inflection in FY18 is coming. 5. Goldman Sachs analyst Jami Rubin added BioMarin (BMRN) and Alnylam (ALNY) to the firm's Conviction Buy List, upgrading them both from Buy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/19/17
SBSH
12/19/17
NO CHANGE
Target $54
SBSH
Buy
Citi names Foot Locker top Apparel and Footwear pick for 2018
Citi analyst Kate McShane moved Foot Locker (FL) to number one from number five on her Apparel and Footwear picks list for 2018. Even though the stock is up 46% since the Q3 results on November 17, it remains down 34% year-to-date, McShane tells investors in a research note. The analyst expects earnings estimates to move higher in 2018 as comps drop less than expected, the outlook for Q4 is improved and positive highlights are given on the company's product pipeline. McShane raised her price target for Foot Locker shares to $54 from $47 and keeps a Buy rating on the shares.
12/19/17
WEDB
12/19/17
NO CHANGE
Target $33
WEDB
Outperform
Shoe Carnival price target raised to $33 from $27 at Wedbush
Wedbush analyst Christopher Svezia raised his price target for Shoe Carnival (SCVL) to $33 from $27 as he believes tax reform is likely to be signed into law. The analyst finds Shoe Carnival, Steven Madden (SHOO), Caleres (CAL), Foot Locker (FL), and Wolverine World Wide (WWW) as having the most upside to current share levels whereas DSW (DSW), Dick's Sporting (DKS), and Under Armour (UAA;UA) appear to have tax reform's impact priced into shares. He reiterates an Outperform rating on Shoe Carnival's shares.
SIG Signet Jewelers
$58.24

1.64 (2.90%)

11/22/17
NEED
11/22/17
NO CHANGE
Target $60
NEED
Buy
Signet Jewelers price target lowered to $60 from $74 at Needham
Needham analyst Rick Patel lowered his price target on Signet Jewelers to $60 after a Q3 earnings miss that led to a stock price plunge of 30%. Patel says the decline was driven by surprising credit-transition headwinds, the cut in guidance, and lower visibility. While the company outlook suggests that these issues may linger and underlying demand for jewelry remains weak, writes the analyst in his research note, the stock now trades within parity of its trough PE valuation. Patel keeps his Buy rating, saying "risk/reward favors upside for investors willing to wait".
11/21/17
WELS
11/21/17
DOWNGRADE
Target $60
WELS
Market Perform
Wells Fargo downgrades Signet Jewelers after 'another stumble'
Wells Fargo analyst Ike Boruchow downgraded Signet Jewelers to Market Perform from Outperform and cut his price target for the shares to $60 from $75. This morning's Q3 earnings report is "another stumble during what has been a very challenging past 18 months," Boruchow tells investors in a post-earnings research note. He believes the company's "meaningful distractions" from new credit arrangements make the shares "extremely difficult to own for the time being." The diamond jewelry retailer is down 29%, or $21.76, to $54.08 in afternoon trading.
11/22/17
NOMU
11/22/17
NO CHANGE
Target $64
NOMU
Buy
Signet Jewelers price target lowered to $64 from $73 at Nomura Instinet
Nomura Instinet analyst Simeon Siegel lowered his price target for Signet Jewelers to $64 after the company cut its outlook. The analyst, however, maintains a Buy rating on the shares. With the stock trading at eight times his lowered fiscal 2019 earnings estimate, the analyst believes Signet's valuation "should provide downside support and with favorable risk reward."
11/22/17
RBCM
11/22/17
NO CHANGE
Target $60
RBCM
Outperform
Signet Jewelers price target lowered to $60 from $66 at RBC Capital
RBC Capital analyst Brian Tunick lowered his price target on Signet Jewelers to $60, saying the Q3 earnings miss questions the managements credibility considering that the 47% stock price appreciation since Q2 was driven by bullish company meetings. The analyst says that while Q3 results were not confidence inspiring, the recovery in comps and upcoming potential catalysts justify an Outperform rating.

TODAY'S FREE FLY STORIES

TWTR

Twitter

$23.66

-0.38 (-1.58%)

14:03
01/20/18
01/20
14:03
01/20/18
14:03
Hot Stocks
Twitter begins notifying users exposed to Russian propaganda during elections »

Twitter, which is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

, SPX

S&P 500

13:58
01/20/18
01/20
13:58
01/20/18
13:58
Periodicals
Government shuts down on anniversary of Trump presidency, Reuters reports »

President's Trump…

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

1.49 (0.83%)

, NYT

New York Times

$21.90

1.7 (8.42%)

13:48
01/20/18
01/20
13:48
01/20/18
13:48
Periodicals
NY Times stock jumps after Facebook's announcement, Recode reports »

Facebook (FB) CEO Mark…

FB

Facebook

$181.29

1.49 (0.83%)

NYT

New York Times

$21.90

1.7 (8.42%)

NWSA

News Corp.

$17.22

0.21 (1.23%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 07

    Feb

  • 28

    Feb

WMT

Walmart

$104.59

0.29 (0.28%)

13:36
01/20/18
01/20
13:36
01/20/18
13:36
Periodicals
Still time to shop Walmart shares as company makes changes, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, NFLX

Netflix

$220.46

0.13 (0.06%)

08:59
01/20/18
01/20
08:59
01/20/18
08:59
Periodicals
Netflix among likely candidates for an Apple purchase, Barron's says »

Especially for tech…

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 01

    Feb

BA

Boeing

$337.73

-2.43 (-0.71%)

08:50
01/20/18
01/20
08:50
01/20/18
08:50
Periodicals
Boeing not a sell just yet, Barron's says »

Boeing stock has come…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, EADSY

Airbus

$28.43

0.755 (2.73%)

08:24
01/20/18
01/20
08:24
01/20/18
08:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$178.46

-0.8 (-0.45%)

EADSY

Airbus

$28.43

0.755 (2.73%)

BA

Boeing

$337.73

-2.43 (-0.71%)

VZ

Verizon

$51.91

0.36 (0.70%)

NYT

New York Times

$21.90

1.7 (8.42%)

TWX

Time Warner

$93.36

0.39 (0.42%)

DIS

Disney

$110.59

0.17 (0.15%)

TIME

Time Inc.

$18.55

0.05 (0.27%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

BAC

Bank of America

$31.72

0.24 (0.76%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BK

BNY Mellon

$56.61

1.26 (2.28%)

WLKP

Westlake Chemical Partners

$24.45

-0.1 (-0.41%)

MON

Monsanto

$120.66

1.8 (1.51%)

DLTR

Dollar Tree

$114.73

1.83 (1.62%)

CE

Celanese

$112.96

1.93 (1.74%)

LYB

LyondellBasell

$119.92

3.03 (2.59%)

TSE

Trinseo

$79.45

2.2 (2.85%)

EYE

National Vision

$43.13

1.12 (2.67%)

ETFC

E-Trade

$54.28

0.63 (1.17%)

LPLA

LPL Financial

$59.03

0.53 (0.91%)

AMTD

TD Ameritrade

$55.17

0.21 (0.38%)

SCHW

Charles Schwab

$55.48

0.15 (0.27%)

ADS

Alliance Data

$261.82

5.88 (2.30%)

FISV

Fiserv

$138.11

0.17 (0.12%)

FLT

FleetCor

$206.65

3.4 (1.67%)

HAWK

Blackhawk

$45.25

0.1 (0.22%)

MTZ

MasTec

$53.30

1.25 (2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 25

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 02

    Feb

  • 06

    Feb

  • 07

    Feb

  • 15

    Feb

  • 16

    Feb

  • 21

    Feb

  • 08

    Mar

  • 18

    Mar

CME

CME Group

$154.28

2.07 (1.36%)

, GS

Goldman Sachs

$256.12

5.15 (2.05%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Bar Association to hold annual meeting »

Derivatives & Futures…

CME

CME Group

$154.28

2.07 (1.36%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BP

BP

$42.40

-0.5 (-1.17%)

C

Citi

$78.30

0.91 (1.18%)

BAC

Bank of America

$31.72

0.24 (0.76%)

CS

Credit Suisse

$19.06

0.13 (0.69%)

CRL

Charles River

$107.89

1.22 (1.14%)

MS

Morgan Stanley

$57.46

1.62 (2.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 15

    Feb

AMGN

Amgen

$189.28

1.69 (0.90%)

, BAYRY

Bayer

$32.05

0.235 (0.74%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2018 ASCO…

AMGN

Amgen

$189.28

1.69 (0.90%)

BAYRY

Bayer

$32.05

0.235 (0.74%)

BLRX

BioLineRx

$1.09

-0.02 (-1.80%)

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

CELG

Celgene

$102.65

0.93 (0.91%)

DNA

Bought by RHHBY

ESALY

Eisai

$56.88

0.115 (0.20%)

EXEL

Exelixis

$28.00

0.14 (0.50%)

HALO

Halozyme

$17.98

0.13 (0.73%)

INCY

Incyte

$93.16

1.24 (1.35%)

IPSEY

Ipsen

$34.65

0.75 (2.21%)

LXRX

Lexicon

$10.44

0.2 (1.95%)

MGNX

MacroGenics

$19.19

0.3 (1.59%)

MRK

Merck

$61.28

0.15 (0.25%)

NVS

Novartis

$86.94

0.53 (0.61%)

SNY

Sanofi

$44.60

0.09 (0.20%)

ONCY

Oncolytics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 02

    Feb

  • 03

    Feb

  • 05

    Feb

  • 08

    Feb

  • 15

    Feb

  • 16

    Feb

  • 02

    Mar

  • 05

    Mar

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 30

    Apr

  • 02

    May

  • 17

    May

  • 28

    May

  • 23

    Oct

WLFC

Willis Lease

$26.66

0.05 (0.19%)

18:59
01/19/18
01/19
18:59
01/19/18
18:59
Hot Stocks
Willis Lease announces $1,000 bonus for employees »

Willis Lease announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPS

Dr Pepper Snapple

$96.35

1.03 (1.08%)

18:13
01/19/18
01/19
18:13
01/19/18
18:13
Hot Stocks
Dr Pepper to become official sponsor of esports team TSM »

Dr Pepper announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$11.70

0.09 (0.78%)

17:53
01/19/18
01/19
17:53
01/19/18
17:53
Hot Stocks
Vintage Capital in standstill pact with Rent-A-Center »

On January 17, Vintage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AR

Antero Resources

$18.74

-0.59 (-3.05%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Recommendations
Antero Resources analyst commentary at MUFG »

Antero Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.21

0.06 (0.16%)

, TWX

Time Warner

$93.36

0.39 (0.42%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Periodicals
AT&T requesting docs from companies in Time Warner deal hearing, Reuters says »

AT&T (T) is…

T

AT&T

$37.21

0.06 (0.16%)

TWX

Time Warner

$93.36

0.39 (0.42%)

VZ

Verizon

$51.91

0.36 (0.70%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

DISH

Dish

$45.26

0.1 (0.22%)

CHTR

Charter

$366.05

0.8 (0.22%)

DIS

Disney

$110.59

0.17 (0.15%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 08

    Feb

  • 08

    Feb

GRPN

Groupon

$5.57

0.46 (9.00%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Hot Stocks
Groupon announces Chief Product Officer Jay Sullivan resigns »

On January 17, Jay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$102.65

0.93 (0.91%)

17:41
01/19/18
01/19
17:41
01/19/18
17:41
Hot Stocks
Celgene's Abraxane exceeds primary endpoint target in pancreatic cancer trial »

Celgene announced primary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

VALU

Value Line

$19.60

0.3 (1.55%)

17:40
01/19/18
01/19
17:40
01/19/18
17:40
Hot Stocks
Value Line reaffirms $3M stock repurchase program »

The Board of Directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALU

Value Line

$19.60

0.3 (1.55%)

17:39
01/19/18
01/19
17:39
01/19/18
17:39
Hot Stocks
Value Line declares special dividend of 20c per share »

Payable on March 9 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZEAL

Zealand Pharma

$15.05

-0.78 (-4.93%)

17:34
01/19/18
01/19
17:34
01/19/18
17:34
Hot Stocks
Zealand Pharma: FDA approves IND for Phase 3 trials of dasiglucagon in CHI »

The U.S. FDA has approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMSF

Genmab

$190.75

2.75 (1.46%)

, JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

17:29
01/19/18
01/19
17:29
01/19/18
17:29
Hot Stocks
Genmab says FDA grants priority review for daratumumab »

Genmab (GNMSF) announced…

GNMSF

Genmab

$190.75

2.75 (1.46%)

JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

HII

Huntington Ingalls

$242.12

5.24 (2.21%)

17:21
01/19/18
01/19
17:21
01/19/18
17:21
Hot Stocks
Huntington Ingalls awarded $125.2M government contract modification »

Huntington Ingalls Inc. -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 21

    Feb

BAESY

BAE Systems

$33.30

0.18 (0.54%)

, GD

General Dynamics

$209.10

1.3 (0.63%)

17:20
01/19/18
01/19
17:20
01/19/18
17:20
Hot Stocks
BAE Systems, General Dynamics awarded $237.6M government contract modification »

BAE Systems (BAESY) San…

BAESY

BAE Systems

$33.30

0.18 (0.54%)

GD

General Dynamics

$209.10

1.3 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

SYRS

Syros Pharmaceuticals

$10.80

0.27 (2.56%)

17:17
01/19/18
01/19
17:17
01/19/18
17:17
Syndicate
Breaking Syndicate news story on Syros Pharmaceuticals »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTFC

Wintrust Financial

$87.81

0.96 (1.11%)

17:13
01/19/18
01/19
17:13
01/19/18
17:13
Hot Stocks
Wintrust Financial raises its minimum wage to $15 per hour »

Wintrust Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TWTR

Twitter

$23.66

-0.38 (-1.58%)

17:07
01/19/18
01/19
17:07
01/19/18
17:07
Hot Stocks
Twitter says has identified more IRA and automated Russia-based accounts »

In a statement on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.